Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 497,000 shares, an increase of 228.5% from the November 30th total of 151,300 shares. Approximately 5.6% of the company’s shares are sold short. Based on an average trading volume of 1,660,000 shares, the days-to-cover ratio is presently 0.3 days.

Windtree Therapeutics Price Performance

Shares of WINT opened at $0.31 on Friday. The firm has a market capitalization of $2.79 million, a price-to-earnings ratio of -0.02 and a beta of 0.54. Windtree Therapeutics has a 1-year low of $0.29 and a 1-year high of $14.75. The company has a 50-day moving average of $0.54 and a 200 day moving average of $3.36.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating and issued a $7.00 target price on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.